MCID: THY023
MIFTS: 65

Thymoma

Categories: Cancer diseases, Immune diseases, Endocrine diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Thymoma

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to thymoma, familial and spindle cell thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Akt Signaling. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the thymus, thymus and lung, and related phenotypes are nephrotic syndrome and xerostomia

Wikipedia : 76 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 thymoma, familial 34.7 HRAS KIT
2 spindle cell thymoma 33.7 CD5 LCK
3 epithelial malignant thymoma 33.7 CD5 LCK
4 mixed type thymoma 33.6 CD5 KIT
5 dendritic cell thymoma 33.5 CD5 LCK TTN
6 thymic epithelial tumor 32.8 CD5 KIT
7 cortical thymoma 32.7 CD2 TTN
8 thymus cancer 31.5 CD5 DNTT DPYSL5 KIT NKX2-1
9 myasthenia gravis 31.4 AIRE CTLA4 IL2 RYR1 TTN
10 autoimmune addison disease 29.8 AIRE CTLA4
11 alopecia areata 29.6 AIRE CTLA4 IL2
12 follicular dendritic cell sarcoma 29.3 EVPL KIT PPL
13 lymphoblastic lymphoma 29.2 CD5 DNTT PTPRC
14 pemphigus foliaceus 29.2 CTLA4 EVPL PPL
15 lymphoma, non-hodgkin, familial 28.4 CD5 DNTT IL2 PTPRC
16 immunodeficiency with thymoma 12.2
17 invasive malignant thymoma 12.0
18 type c thymoma 12.0
19 encapsulated thymoma 12.0
20 combined thymoma 12.0
21 thymoma type b 12.0
22 predominantly cortical thymoma 11.9
23 malignant type ab thymoma 11.9
24 noninvasive malignant thymoma 11.9
25 malignant type a thymoma 11.9
26 thymoma type a 11.8
27 thymoma type ab 11.8
28 good syndrome 11.8
29 thymoma, childhood 11.8
30 pure red-cell aplasia 11.3
31 acquired pure red cell aplasia 11.2
32 limbic encephalitis with lgi1 antibodies 10.9
33 maxillary sinus adenoid cystic carcinoma 10.8 IL2 KIT
34 chromosome 14q11-q22 deletion syndrome 10.7 HRAS NKX2-1
35 integumentary system cancer 10.6 AKT1 HRAS KIT
36 myasthenia gravis congenital 10.6
37 lung adenoid cystic carcinoma 10.6 HRAS KIT NKX2-1
38 hemangioma of lung 10.6 AKT1 NKX2-1
39 gastrointestinal system cancer 10.5 AKT1 HRAS KIT
40 ovarian melanoma 10.5 HRAS KIT
41 respiratory system cancer 10.5 AKT1 HRAS NKX2-1
42 small cell carcinoma 10.4 KIT NKX2-1 PTPRC
43 sm-ahnmd 10.4 CD2 KIT
44 lobomycosis 10.3 AIRE CD2
45 diffuse cutaneous mastocytosis 10.3 KIT PTPRC
46 extracutaneous mastocytoma 10.3 CD2 KIT PTPRC
47 type 1 diabetes mellitus 17 10.2 AIRE CTLA4
48 myeloma, multiple 10.2 AKT1 HRAS IL2 PTPRC
49 cd45 deficiency 10.2 CD5 LCK PTPRC
50 sarcomatoid squamous cell skin carcinoma 10.2 KIT PTPRC

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

32 (show all 29)
# Description HPO Frequency HPO Source Accession
1 nephrotic syndrome 32 occasional (7.5%) HP:0000100
2 xerostomia 32 occasional (7.5%) HP:0000217
3 ptosis 32 frequent (33%) HP:0000508
4 diplopia 32 frequent (33%) HP:0000651
5 skin rash 32 occasional (7.5%) HP:0000988
6 keratoconjunctivitis sicca 32 occasional (7.5%) HP:0001097
7 arthritis 32 occasional (7.5%) HP:0001369
8 limitation of joint mobility 32 occasional (7.5%) HP:0001376
9 alopecia 32 occasional (7.5%) HP:0001596
10 pericarditis 32 occasional (7.5%) HP:0001701
11 pancytopenia 32 occasional (7.5%) HP:0001876
12 hemolytic anemia 32 occasional (7.5%) HP:0001878
13 dysphagia 32 frequent (33%) HP:0002015
14 dyspnea 32 frequent (33%) HP:0002094
15 abnormality of the pleura 32 occasional (7.5%) HP:0002103
16 abnormality of the peritoneum 32 occasional (7.5%) HP:0002585
17 lymphadenopathy 32 frequent (33%) HP:0002716
18 fatigable weakness 32 frequent (33%) HP:0003473
19 decreased antibody level in blood 32 occasional (7.5%) HP:0004313
20 interstitial pulmonary abnormality 32 frequent (33%) HP:0006530
21 b lymphocytopenia 32 occasional (7.5%) HP:0010976
22 fatigue 32 frequent (33%) HP:0012378
23 cough 32 frequent (33%) HP:0012735
24 myocarditis 32 occasional (7.5%) HP:0012819
25 abnormality of the mediastinum 32 hallmark (90%) HP:0045026
26 neoplasm of the thymus 32 hallmark (90%) HP:0100521
27 myositis 32 occasional (7.5%) HP:0100614
28 thyroiditis 32 occasional (7.5%) HP:0100646
29 chest pain 32 frequent (33%) HP:0100749

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

26 (show all 48)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.9 HRAS
2 Decreased viability GR00221-A-1 10.9 AKT3 KIT HRAS LCK AKT2 AKT1
3 Decreased viability GR00221-A-2 10.9 AKT3 HRAS LCK TTN AKT1
4 Decreased viability GR00221-A-3 10.9 AKT3 HRAS LCK AKT2 AKT1
5 Decreased viability GR00221-A-4 10.9 AKT3 TTN AKT2 AKT1
6 Decreased viability GR00301-A 10.9 AKT3 KIT LCK AKT2
7 Decreased viability GR00342-S-1 10.9 TTN LCK
8 Decreased viability GR00342-S-3 10.9 TTN LCK AKT2
9 Decreased viability GR00402-S-2 10.9 KIT AKT3 HRAS LCK TTN AKT1
10 Decreased substrate adherent cell growth GR00193-A-1 10 KIT AKT2
11 Decreased substrate adherent cell growth GR00193-A-2 10 AKT3 KIT LCK AKT2
12 Decreased substrate adherent cell growth GR00193-A-3 10 AKT3 LCK AKT2
13 Decreased substrate adherent cell growth GR00193-A-4 10 KIT LCK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.91 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.91 AKT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.91 AKT2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.91 AKT2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 AKT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 LCK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.91 LCK
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.91 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.91 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.91 AKT2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.91 AKT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 AIRE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.91 AKT3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 AKT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 AIRE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.91 LCK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.91 LCK
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 LCK
33 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.91 LCK
34 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 KIT
35 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.91 AKT2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.91 AKT3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.91 KIT AKT1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.91 AIRE
39 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.91 AKT3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.91 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.91 AKT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.91 AIRE
44 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 AKT3 LCK KIT AIRE AKT2 AKT1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.91 KIT
46 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.91 KIT
47 Decreased cell migration GR00055-A-1 9.72 AKT3 AKT2 HRAS LCK AKT1
48 Increased cell viability after pRB stimulation GR00230-A-1 9.35 KIT AKT3 LCK AKT2 AKT1

MGI Mouse Phenotypes related to Thymoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 AKT2 AIRE AKT3 AKT1 CTLA4 PTPRC
2 endocrine/exocrine gland MP:0005379 10.24 AKT2 AIRE AKT3 AKT1 CTLA4 PTPRC
3 cardiovascular system MP:0005385 10.22 CTLA4 AKT3 AKT1 RYR1 TTN IL2
4 hematopoietic system MP:0005397 10.22 AKT2 AIRE AKT3 CD5 AKT1 CTLA4
5 immune system MP:0005387 10.21 AKT2 AIRE AKT3 CD5 AKT1 CTLA4
6 digestive/alimentary MP:0005381 10.11 AIRE CTLA4 PTPRC RYR1 KIT HRAS
7 integument MP:0010771 10.01 CTLA4 AKT2 CD5 AKT1 RYR1 EVPL
8 normal MP:0002873 10 AIRE AKT3 AKT1 CD2 CD5 CTLA4
9 neoplasm MP:0002006 9.97 AIRE AKT3 AKT1 AKT2 PTPRC KIT
10 liver/biliary system MP:0005370 9.91 CTLA4 AKT2 AIRE AKT1 PTPRC IL2
11 no phenotypic analysis MP:0003012 9.86 AKT2 AIRE CD5 PTPRC KIT HRAS
12 respiratory system MP:0005388 9.65 AKT2 AIRE AKT1 CTLA4 RYR1 PTPRC
13 skeleton MP:0005390 9.28 CTLA4 AKT2 AKT1 PTPRC RYR1 TTN

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antimetabolites Phase 4
6 Antimetabolites, Antineoplastic Phase 4
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
8 Antirheumatic Agents Phase 4,Phase 1,Phase 2
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Liver Extracts Phase 3,Phase 1,Phase 2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Etoposide phosphate Phase 3,Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Adjuvants, Anesthesia Phase 3
24 Analgesics Phase 3,Phase 1,Phase 2
25 Analgesics, Opioid Phase 3
26 Anesthetics Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Central Nervous System Depressants Phase 3
30 Narcotics Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Methylprednisolone acetate Phase 3,Phase 2
33 Methylprednisolone Hemisuccinate Phase 3,Phase 2
34 Prednisolone acetate Phase 3,Phase 2
35 Prednisolone hemisuccinate Phase 3,Phase 2
36 Prednisolone phosphate Phase 3,Phase 2
37 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
39
Melphalan Approved Phase 2,Not Applicable 148-82-3 4053 460612
40
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
41
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
45
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
46
Busulfan Approved, Investigational Phase 2 55-98-1 2478
47
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
48
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
50
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
6 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
7 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
8 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
9 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
10 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
11 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
12 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2 Octreotide
13 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
14 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
15 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
16 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
17 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
18 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2 Octreotide-LAR
19 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
20 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
21 Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults Completed NCT00376935 Phase 2 Palifermin;Palifermin placebo
22 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
23 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Completed NCT00054132 Phase 2 Erlotinib Hydrochloride
24 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
25 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
26 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
27 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
28 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
29 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
30 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
31 K-BASKET, TAS-117, PI3K/AKT Gene Aberration Recruiting NCT03017521 Phase 2 TAS-117
32 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
33 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
34 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2 Amphotericin B
35 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
36 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
37 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
38 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Active, not recruiting NCT01301391 Phase 2 Milciclib Maleate
39 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Active, not recruiting NCT02220855 Phase 2 BKM120
40 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
41 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
42 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
43 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2 Milciclib Maleate
44 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2 Akt Inhibitor MK2206
45 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2 Akt Inhibitor GSK2141795;Trametinib
46 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2 Sunitinib
47 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
48 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Not yet recruiting NCT02607631 Phase 2 Pembrolizumab
49 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
50 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Suspended NCT03463460 Phase 2 Sunitinib Malate

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

19
The Thymus

MalaCards organs/tissues related to Thymoma:

41
Thymus, Lung, T Cells, Thyroid, Testes, Skin, Liver

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 1156)
# Title Authors Year
1
Spontaneous malignant myoid thymoma in an aged female Fischer 344 rat. ( 29750002 )
2018
2
Wnt4 overexpression promotes thymoma development through a JNK-mediated planar cell polarity-like pathway. ( 29387212 )
2018
3
Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. ( 29713553 )
2018
4
Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. ( 29335856 )
2018
5
Rapidly progressive subacute motor neuronopathy disclosing type B2 thymoma. ( 29364399 )
2018
6
Respiratory insufficiency from myasthenia gravis and polymyositis due to malignant thymoma triggering Takotsubo syndrome. ( 29883223 )
2018
7
Video-assisted thoracoscopic thymectomy for thymoma: a single-center experience. ( 29411632 )
2018
8
Anterior mediastinal leiomyosarcoma mimicking thymoma: A case report. ( 29924013 )
2018
9
Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. ( 29409729 )
2018
10
Thymoma. A Systemic Disease? ( 29801679 )
2018
11
Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? ( 29850899 )
2018
12
Progressive multifocal leukoencephalopathy associated with thymoma with immunodeficiency: a case report and literature review. ( 29631544 )
2018
13
Comparative Analysis of V-Akt Murine Thymoma Viral Oncogene Homolog 3 <i>(AKT3)</i> Gene between Cow and Buffalo Reveals Substantial Differences for Mastitis. ( 29862252 )
2018
14
Rationale and early outcomes for the management of thymoma with proton therapy. ( 29876309 )
2018
15
Thymoma-associated multiorgan autoimmunity with exclusive gastrointestinal tract involvement: case report and review of the literature. ( 29374317 )
2018
16
Robotic-assisted thymectomy for early-stage thymoma: a propensity-score matched analysis. ( 29705833 )
2018
17
Combined operation for thymoma with myasthenia gravis and coronary artery disease in an octogenarian. ( 29924495 )
2018
18
Advanced-Stage Thymoma Associating Multiple Paraneoplastic Syndromes with Good Response to Oral Corticosteroids and Topical Tacrolimus. ( 29887166 )
2018
19
Thymoma metastasis: Differential diagnosis of pleural nodules and masses. ( 29970789 )
2018
20
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. ( 29945642 )
2018
21
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
22
Long-term survival after R0 resection of thymoma. ( 29945456 )
2018
23
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. ( 29702286 )
2018
24
MSA Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. ( 29416500 )
2018
25
Dosimetric benefit of adaptive radiotherapy in the neoadjuvant management of canine and feline thymoma-An exploratory case series. ( 29316134 )
2018
26
Myasthenia gravis appearing after thymectomy heralding recurrent thymoma. ( 29768973 )
2018
27
Type A thymoma presenting with bone metastasis. ( 29855070 )
2018
28
Assessment of Lymphoid Molecular Clonality in Canine Thymoma. ( 29422318 )
2018
29
Core Needle Biopsy of an Anterior Mediastinal Thymoma: Creation of a Safe Access Route by Hydrodissection. ( 29373145 )
2018
30
Good's Syndrome-Association of the Late Onset Combined Immunodeficiency with Thymoma: Review of Literature and Case Report. ( 29512373 )
2018
31
Middle Mediastinal Thymoma. ( 29733825 )
2018
32
A cornerstone is laid on the great wall of thymoma knowledge. ( 29859677 )
2018
33
Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma. ( 28299711 )
2017
34
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy. ( 28838398 )
2017
35
Paraneoplastic Pemphigus Associated with a Malignant Thymoma: A Case of Persistent and Refractory Oral Ulcerations Following Thymectomy. ( 28392652 )
2017
36
Thymoma-associated multi-organ autoimmunity: two cases and a review of the literature. ( 28052464 )
2017
37
Editorial: pleural recurrence of thymoma-what is the value of intra-thoracic chemo-hyperthermia? ( 29268347 )
2017
38
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
39
Epidural Metastasis in Malignant Thymoma Mimicking Epidural Abscess: Case Report and Literature Review. ( 29301178 )
2017
40
Maxillary Sinus Kaposi Sarcoma: Case Report in an HIV-Negative Patient with Thymoma. ( 29204303 )
2017
41
Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. ( 28739760 )
2017
42
Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit inA the Setting of the FutureA Adoption of the IASLC-ITMIG TNM-Based Staging System. ( 27988104 )
2017
43
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? ( 29268390 )
2017
44
Correlations of TNF-I+ gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population. ( 28429750 )
2017
45
Corrigendum to 'High rate of unnecessary thymectomy and its cause. Can computed tomography distinguish thymoma, lymphoma, thymic hyperplasia, and thymic cysts?' [EURR 84 (3) (2015) 524-533]. ( 28238381 )
2017
46
Secondary systemic lupus erythematosus after thymoma resection misdiagnosed as medically unexplained dyspnoea: A case report. ( 29310389 )
2017
47
THYMOMA: A clinicopathological correlation of 1470 cases. ( 28851660 )
2017
48
Ectopic Hamartomatous Thymoma: A Review Of The Literature With Report Of New Cases And Proposal Of A New Name: Biphenotypic Branchioma. ( 28879635 )
2017
49
A Case of Paraneoplastic Limbic Encephalitis in a Patient with Invasive Thymoma with Anti-Glutamate Receptor Antibody-Positive Cerebrospinal Fluid: A Case Report. ( 29269707 )
2017
50
Different neurologic outcomes of myasthenia gravis with thymic hyperplasia and thymoma after extended thymectomy: A single center experience. ( 29246632 )
2017

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6
(show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
2 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh38 Chromosome 4, 54727444: 54727444
3 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
4 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
5 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh37 Chromosome 4, 55592144: 55592144
6 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh38 Chromosome 4, 54725978: 54725978
7 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh37 Chromosome 4, 55593591: 55593591
8 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh38 Chromosome 4, 54727425: 54727425
9 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Likely pathogenic rs121913235 GRCh38 Chromosome 4, 54727437: 54727437
10 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Likely pathogenic rs121913235 GRCh37 Chromosome 4, 55593603: 55593603
11 KIT NM_000222.2(KIT): c.1679_1681delTTG (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh37 Chromosome 4, 55593612: 55593614
12 KIT NM_000222.2(KIT): c.1679_1681delTTG (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh38 Chromosome 4, 54727447: 54727449
13 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh37 Chromosome 4, 55593661: 55593661
14 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh38 Chromosome 4, 54727495: 54727495
15 KIT NM_000222.2(KIT): c.1730_1738delCTTATGATC (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 GRCh37 Chromosome 4, 55593664: 55593672
16 KIT NM_000222.2(KIT): c.1730_1738delCTTATGATC (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 GRCh38 Chromosome 4, 54727498: 54727506
17 KIT NM_000222.2(KIT): c.2089C> T (p.His697Tyr) single nucleotide variant Uncertain significance rs763308199 GRCh37 Chromosome 4, 55595599: 55595599
18 KIT NM_000222.2(KIT): c.2089C> T (p.His697Tyr) single nucleotide variant Uncertain significance rs763308199 GRCh38 Chromosome 4, 54729433: 54729433
19 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh37 Chromosome 4, 55599334: 55599334
20 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh38 Chromosome 4, 54733168: 54733168

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 AKT1 AKT2 AKT3 HRAS IL2 KIT
2
Show member pathways
13.49 AKT1 AKT2 AKT3 CD2 HRAS IL2
3
Show member pathways
13.47 AKT1 AKT2 AKT3 CTLA4 HRAS KIT
4
Show member pathways
13.47 AKT1 AKT2 AKT3 DPYSL5 EVPL HRAS
5
Show member pathways
13.36 AKT1 AKT2 AKT3 CD2 HRAS IL2
6
Show member pathways
13.33 AKT1 AKT2 AKT3 CD2 HRAS IL2
7
Show member pathways
13.1 AKT1 AKT2 AKT3 HRAS IL2 KIT
8
Show member pathways
13.05 AKT1 AKT2 AKT3 HRAS IL2 KIT
9
Show member pathways
12.94 AKT1 AKT2 AKT3 CTLA4 HRAS LCK
10
Show member pathways
12.93 AKT1 AKT2 AKT3 HRAS KIT
11 12.89 AKT1 AKT2 AKT3 HRAS IL2 KIT
12 12.84 AKT1 AKT2 AKT3 HRAS KIT
13
Show member pathways
12.83 AKT1 AKT2 AKT3 HRAS KIT
14
Show member pathways
12.8 AKT1 AKT2 AKT3 HRAS KIT
15
Show member pathways
12.8 AKT1 AKT2 AKT3 HRAS RYR1
16
Show member pathways
12.77 AKT1 AKT2 AKT3 HRAS IL2 LCK
17
Show member pathways
12.75 AKT1 AKT2 AKT3 HRAS KIT LCK
18
Show member pathways
12.71 AKT1 AKT2 AKT3 HRAS NKX2-1
19
Show member pathways
12.7 AKT1 AKT2 AKT3 HRAS IL2
20
Show member pathways
12.67 AKT1 AKT2 AKT3 HRAS IL2
21
Show member pathways
12.66 AKT1 AKT2 AKT3 HRAS PTPRC
22
Show member pathways
12.64 AKT1 AKT2 AKT3 LCK
23
Show member pathways
12.61 AKT1 AKT2 AKT3 CTLA4 LCK
24
Show member pathways
12.57 AKT1 AKT2 AKT3 HRAS LCK PTPRC
25 12.56 CD2 CTLA4 IL2 KIT LCK PTPRC
26
Show member pathways
12.54 AKT1 AKT2 AKT3 HRAS
27
Show member pathways
12.54 AKT1 AKT2 AKT3 HRAS
28
Show member pathways
12.5 AKT1 AKT2 AKT3 HRAS
29
Show member pathways
12.5 AKT1 AKT2 AKT3 HRAS
30
Show member pathways
12.49 AKT1 AKT2 AKT3 HRAS IL2
31
Show member pathways
12.46 AKT1 AKT2 AKT3 HRAS
32
Show member pathways
12.44 AKT1 AKT2 AKT3 HRAS KIT
33
Show member pathways
12.41 AKT1 AKT2 AKT3 HRAS
34
Show member pathways
12.41 AKT1 AKT2 AKT3 HRAS RYR1
35
Show member pathways
12.39 AKT1 AKT2 AKT3 HRAS
36
Show member pathways
12.39 AKT1 AKT2 AKT3 HRAS
37 12.39 AKT1 AKT2 AKT3 HRAS IL2 LCK
38
Show member pathways
12.38 AKT1 AKT2 AKT3 HRAS
39 12.36 AKT1 AKT2 AKT3 HRAS
40
Show member pathways
12.33 AKT1 AKT2 AKT3 HRAS LCK PTPRC
41
Show member pathways
12.31 AKT1 AKT2 AKT3 HRAS
42
Show member pathways
12.26 AKT1 AKT2 AKT3 HRAS LCK PTPRC
43
Show member pathways
12.25 AKT1 AKT2 AKT3 HRAS
44 12.25 AKT1 AKT2 AKT3 HRAS
45
Show member pathways
12.23 AKT1 AKT2 AKT3 HRAS IL2
46 12.22 AKT1 AKT2 AKT3 HRAS
47
Show member pathways
12.22 AKT1 AKT2 AKT3 HRAS
48
Show member pathways
12.22 AKT1 AKT2 AKT3 CTLA4 LCK
49
Show member pathways
12.21 AKT1 AKT2 AKT3 HRAS
50
Show member pathways
12.21 AKT1 AKT2 AKT3 HRAS

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CD2 CD5 CTLA4 KIT PTPRC

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 AKT1 AKT2 HRAS IL2 KIT
2 phosphorylation GO:0016310 9.91 AKT1 AKT2 AKT3 KIT LCK TTN
3 positive regulation of gene expression GO:0010628 9.8 AKT1 HRAS KIT NKX2-1 TTN
4 protein phosphorylation GO:0006468 9.8 AKT1 AKT2 AKT3 KIT LCK TTN
5 B cell receptor signaling pathway GO:0050853 9.71 CTLA4 LCK PTPRC
6 positive regulation of protein phosphorylation GO:0001934 9.67 AKT1 AKT2 HRAS IL2
7 mammary gland epithelial cell differentiation GO:0060644 9.51 AKT1 AKT2
8 peripheral nervous system myelin maintenance GO:0032287 9.49 AKT1 AKT2
9 positive regulation of mitochondrial membrane potential GO:0010918 9.48 AKT1 AKT2
10 positive regulation of glucose metabolic process GO:0010907 9.46 AKT1 AKT2
11 release of sequestered calcium ion into cytosol GO:0051209 9.33 LCK PTPRC RYR1
12 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT1 AKT2
13 T cell costimulation GO:0031295 9.26 AKT1 CD5 CTLA4 LCK
14 T cell differentiation GO:0030217 8.92 IL2 KIT LCK PTPRC

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AIRE AKT1 AKT2 AKT3 CD2 CD5
2 kinase activity GO:0016301 9.63 AKT1 AKT2 AKT3 KIT LCK TTN
3 protein kinase activity GO:0004672 9.1 AKT1 AKT2 AKT3 KIT LCK TTN

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....